Introduction {#Sec1}
============

Ebola virus (EBOV) is one of the re-emerging viruses with a high mortality rate of up to 90% (Bhattacharyya and Hope [@CR2]; Shurtleff et al. [@CR29]). EBOV belongs to the filovirus family and affects the liver (Pallesen et al. [@CR24]). EBOV requires different host factors during the life cycle (Cantoni and Rossman [@CR3]; Ibrahim et al. [@CR16]). The 2015 outbreak of EBOV caused more than 10,000 deaths with hemorrhagic fever as the main characteristic effect (El gohary et al. [@CR7]). The ease with which the virus spread (via body fluids) and its high mortality rate made EBOV a global health threat of international concern (El gohary et al. [@CR7]). The current development in drug design to eradicate the virus, using direct-acting antivirals (DAA), has reduced the momentum of viral spreading (Elfiky [@CR8]; Gonzalez-Grande et al. [@CR14]; Yang et al. [@CR35]).

The upregulation of specific cellular proteins that mediate the alleviation mechanisms to reduce stress is induced by the unfolded protein response (UPR) mechanism in stressed cells. Heat shock proteins (HSP), the chaperones, are among those proteins that are upregulated under stress, as in viral infection or some types of cancers (Ibrahim et al. [@CR16]). Glucose-regulated protein 78 (GRP78), a member named HSPA5 (Kampinga et al. [@CR18]) of the HSP70 chaperone family is termed the master of the UPR mechanism in the lumen of the endoplasmic reticulum (ER) (Gething and Sambrook [@CR13]; Ibrahim et al. [@CR16]; Lee [@CR21]; Li and Lee [@CR22]; Quinones et al. [@CR25]; Rao et al. [@CR26]). Under cellular stressors, HSPA5 releases activating transcription factor 6 (ATF6), protein kinase RNA-like endoplasmic reticulum kinase (PERK), and inositol-requiring enzyme 1 (IRE1) because of the accumulation of unfolded proteins. The released enzymes cause inhibition of protein synthesis and enhancement of refolding mechanisms (Ibrahim et al. [@CR16]; Shen et al. [@CR28]). Subsequently, HSPA5 is upregulated and succeeds in escaping the ER retention (detected in the cytoplasm and over the cell membrane (cell-surface HSPA5)) (Ibrahim et al. [@CR16]; Wu et al. [@CR34]). Cell-surface HSPA5 is susceptible to pathogen recognition by viral envelope glycoproteins or fungal coat proteins (Gebremariam et al. [@CR12]; Ibrahim et al. [@CR16]). Pep42, a cyclic 13-residues peptide (CTVALPGGYVRVC) targets specifically cell-surface HSPA5 in vivo (Kim et al. [@CR19]). It is used to deliver the chemotherapeutic, doxorubicin, to cancer cells presenting cell-surface HSPA5 (Ibrahim et al. [@CR16]; Martin et al. [@CR23]). Additionally, HSPA5 is reported to be associated with some viral proteins like spike protein in coronaviruses and E6 in human papillomavirus while the binding site was predicted (Elfiky [@CR9]; Ibrahim et al. [@CR17]). It was reported that HSPA5 is associated with EBOV in ER (Shurtleff et al. [@CR29]). It was suggested that HSPA5 could be used as a drug target to stop EBOV infection (Shurtleff et al. [@CR29]). In addition, EBOV glycoproteins GP1 and GP2 have been shown to accumulate in the ER of the infected cells, causing stress response (Bhattacharyya and Hope [@CR2]).

In this work, the binding site between cell-surface HSPA5 and viral GP1 protein is predicted based on sequence, and thus, Pep42 is an example of a class of drugs that may reduce EBOV infections. Protein/peptide and protein/protein docking are employed to explore such binding using the protein/protein docking software "HADDOCK" which utilizes solvation and molecular dynamics simulation (MDS) in refining the interacting residues (binding site) for the interactions formed to be trustful (van Dijk and Bonvin [@CR31]). In addition, HPEPDOCK constructs different possible conformations of the peptide and tests the binding affinity of each of the predicted structures against the target protein (Zhou et al. [@CR40]).

Materials and methods {#Sec2}
=====================

Nine solved structures for EBOV glycoproteins are found in the Protein Data Bank (Berman et al. [@CR1]) with the following codes: 5JQ3, 6QD7, 6QD8, 6MAM, 6EA7, 5KEL, 5KEN, 6EA5, and 5KEM with a resolution of 2.23, 3.10, 3.30, 4.10, 4.25, 4.30, 4.30, 4.75, and 5.50 Å, respectively (Ehrhardt et al. [@CR6]; Pallesen et al. [@CR24]; West et al. [@CR32], [@CR33]). Four of these structures are solved by x-ray crystallography (5JQ3, 6MAM, 6EA7, and 6EA5), while the rest are solved by cryo-electron microscopy. All the solved structures have been released during the past 3 years. The PDB files and their corresponding FASTA sequence files are downloaded from the Protein Data Bank database (PDB). By the aid of PyMOL software (DeLano [@CR5]), water, ions, and protein chains other than EBOV GP1 are removed from the PDB files. The same is done with the only available wild-type and full-length HSPA5 (x-ray crystallography solved structure PDB ID: 5E84 with 2.99 Å resolution) in the open conformation (Yang et al. [@CR36]; Yang et al. [@CR37]). It is important to use the open conformation of the HSP5A in which the SBDα and SBDβ are apart from each other, and the substrate affinity to SBDβ is higher (Chiappori et al. [@CR4]). The available sequences for EBOV GP1 found in the protein database of the National Center for Biotechnology Information (NCBI) are downloaded (ten sequences found in the identical protein group database), and Clustal Omega is utilized to perform multiple sequence alignment (MSA) with the Pep42 sequence CTVALPGGYVRVC (Sievers et al. [@CR30]). ESpript 3.0 is used to represent the MSA (Gouet et al. [@CR15]). The C121--C135 region of EBOV GP1 protein that fits well with Pep42 (33.3% identity) is analyzed by the ProtScale web server (ExPASy Bioinformatics Resource Portal) (Garg et al. [@CR10]; Gasteiger et al. [@CR11]). PyMOL is used to superimpose all the solved structures to show the structural conservation of the C121--C135 region of EBOV GP1.

HADDOCK web server (van Dijk and Bonvin [@CR31]) was utilized to test the recognition of the full-length EBOV GP1 (PDB ID: 5JQ3: A, 6QD7: A, 6QD8: A, 6MAM: G, 6EA7: A, 5KEL: A, 5KEN: A, 6EA5: A, and 5KEM: A) by HSPA5 SDBβ (PDB ID: 5E84: A). For HSPA5, the active residues are selected to be I426, T428, V429, V432, T434, F451, S452, V457, and I459 (Yang et al. [@CR36]). In addition, EBOV GP1 active residues are chosen to be the C121--C135 region. Protein-ligand interaction profiler (PLIP) web server (Salentin et al. [@CR27]) was selected to assess the binding pattern after docking. Pep42 cyclic peptide (CTVALPGGYVRVC) model was built using I-TASSER web server (Zhang [@CR39]). The protein/peptide docking software HPEPDOCK (Zhou et al. [@CR40]) and HADDOCK were utilized to dock the cyclic Pep42 model into the binding site of HSPA5. A blind rigid docking scheme is used in HPEPDOCK without the binding site determination for HSPA5 to scan the possible binding sites. The easy interface of HADDOCK is utilized to dock the cyclic Pep42 peptide (all residues are treated as active) into HSPA5 SBDβ (I426, T428, V429, V432, T434, F451, S452, V457, and I459 are selected to be the active residues).

Results and discussion {#Sec3}
======================

Multiple sequence alignment {#Sec4}
---------------------------

The cyclic peptide Pep42 was reported to selectively target cell-surface HSPA5 (which appears in some types of cancer) and used as a drug carrier for the anti-cancer agent, doxorubicin (Ibrahim et al. [@CR16]; Yoneda et al. [@CR38]). Figure [1a](#Fig1){ref-type="fig"} shows part of the multiple sequence alignment (MSA) between the Pep42 sequence CTVALPGGYVRVC and the ten EBOV GP1 sequences downloaded from the NCBI protein database. A complete MSA is found in the supplementary file (Fig. [S1](#MOESM1){ref-type="media"}). Five identical residues (compared with the Pep42 sequence) were found in the MSA of EBOV GP1 sequences, which are C121, A124, P126, G128, and C135 (the numbering is based on PDB ID: 5JQ3). Interestingly, both C121 and C135 form disulfide bonds (see the green numbers at the bottom of Fig. [1a](#Fig1){ref-type="fig"}) with C147 and C108, respectively. The presence of these disulfides suggests its contribution to the folding of GP1 and GP2, as mentioned in earlier work (Cantoni and Rossman [@CR3]). Moreover, the cyclic peptide (Pep42) can target CS-HSPA5. The C121--C135 region of EBOV GP1 is found in the β-turn region and the loop separating between the β7 and β8 secondary structure (see the top panel of Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1**a** Multiple sequence alignment (MSA) between Pep42 and EBOV GP1 sequences downloaded from the NCBI protein database. The full MSA is presented in the supplementary fig. [S1](#MOESM1){ref-type="media"}. Alignment is made using the Clustal Ω web server and represented by ESpript 3 software. Red highlights indicate identical residues found, while residues written in red are conserved. **b** Hydrophobicity plot (Kyte and Doolittle) for both Pep42 (orange) and EBOV GP1 (C121--C135 region) (gray) peptides. **c** The surface representation of both the Pep42 cyclic peptide and EBOV GP1 C121--C135 region. Hydrophobic residues are colored red, hydrophilic residues in green, and residues with weak hydrophilicity are colored yellowFig. 2Structural superposition of the solved structures for EBOV GP1 (PDB IDs: 5JQ3, 6QD7, 6QD8, 6MAM, 6EA7, 5KEL, 5KEN, 6EA5, and 5KEM) found in the Protein Data Bank. The C121--C135 region in all structures is represented in red cartoons for clarity. Hydrophobic residues L122, I129, and F132 are labeled and represented in lines for the 5JQ3 structure. The right panel shows a 90^°^ rotated view with both cartoon and surface representation to show the surface accessibility of the C121--C135 region

Figure [1b](#Fig1){ref-type="fig"} shows the hydrophobicity as a function of amino acid residues of both the Pep42 and C121--C135 regions of EBOV GP1 sequences. Kyte and Doolittle hydropathic parameters (Kyte and Doolittle [@CR20]) are used by ProtScale web server of the ExPASy bioinformatics resource portal. A high degree of similarity in the hydrophobicity values for the EBOV GP1 C121--C135 region supports the MSA data. The sequence, and thus the structural similarity of EBOV GP1 compared with Pep42, indicates its ability to bind cell-surface HSPA5 substrate-binding domain β (SBDβ). In addition, Fig. [1c](#Fig1){ref-type="fig"} shows the molecular surface of the peptide Pep42 and the C121--C135 region of EBOV GP1. Three colors are used to represent the residues: highly hydrophobic residues in red (such as C, I, L, A, and V), low hydrophilicity residues in yellow (such as G, P, and T), and hydrophilic residues in green (such as D and R). As shown, the two structures show some hydrophobic patch that was reported previously to be the target regions for HSPA5. These hydrophobic residues of EBOV GP1 (C121, L122, A124, A125, I129, F132, and C135) are suggested to be the binding site for cell-surface HSPA5.

Structural conservation {#Sec5}
-----------------------

Figure [2a](#Fig2){ref-type="fig"} shows the structural conservation of the EBOV GP1 C121--C135 region (red-colored cartoon) in all the solved structures (colored cartoons) found in the Protein Data Bank (PDB IDs: 5JQ3, 6QD7, 6QD8, 6MAM, 6EA7, 5KEL, 5KEN, 6EA5, and 5KEM). The root mean square deviation (RMSD) values of the superposition range from 0.35 Å up to 1.9 Å. As shown in the cartoon (lower) and surface representation (upper) of Fig. [2b](#Fig2){ref-type="fig"} (90^°^ rotation on the x-axis of Fig. [2a](#Fig2){ref-type="fig"}), the C121--C135 region is surface exposed (encircled). It can interact with chaperone proteins with its hydrophobic residues L122, I129, and F132 (see the enlarged panel of Fig. [2a](#Fig2){ref-type="fig"} for 5JQ3)

EBOV GP1--HSPA5 docking {#Sec6}
-----------------------

Table [1](#Tab1){ref-type="table"} lists the established interactions upon docking EBOV GP1 solved structures (PDB codes are listed) into HSPA5 SBDβ structure and the docking scores of HADDOCK (average values with the standard deviations calculated for the top-ranked cluster for each EBOV GP1 solved structure). Mainly, two types of interactions are established between EBOV GP1 and HSPA5, H-bonding and hydrophobic interactions. The 6EA5 structure only has two salt bridges formed (E124:K460 and E127 K447 for EBOV GP1--HSPA5). On average, six H-bonds are formed, and four hydrophobic interactions are established upon docking EBOV GP1 into HSPA5.Table 1The interactions formed between EBOV GP1 and GRP78 SBDβ after docking. Nine different docking trials are represented here using different solved structures of EBOV GP1. Analysis made by PLIP web serverEBOV GP1 PDB IDHADDOCK scoreH-bondingHydrophobic interactionNumberAmino acids involved from EBOV GP1Amino acids involved from GRP78NumberAmino acids involved from EBOV GP1Amino acids involved from GRP785JQ3− 89.4 ± 2.88A124A125D127D127G128G128R130T428V429E427T458S452V453S452 (2)4P123P126P126I129V432I426T428F4516QD7− 108.3 ± 6.94A125G128R130V429S452S452 (2)3A124P126D127V432F451I4596QD8− 91.3 ± 4.16A124A125D127G128G128R130T428V429K460S452V453S4526A124P126D127D127I129R130V432I426V457I459F451V4536MAM− 89.3 ± 11.86A124D127D127G128G131C135T428T434Q449Q449S452R4883P126D127P133V429T434V4906EA7− 94.3 ± 2.52A124G131T428S4525A125P126P126D127P133V453T428V429Q449V4905KEL− 97.9 ± 2.54A124A125G128G128T428V429S452V4535P126P126D127D127I129I426F451V457I459F4515KEN− 102.6 ± 3.07C121L122P123A124D127G128I129K460K460E427E427Q449S452S4524A125P126R130V453T428V490 (2)6EA5\*− 99.2 ± 4.57E124E124E127E127G128C135T428K460 (2)T434Q449Q449G4895E124A125P126P126E127I459F451T248V429T4345KEM− 99.9 ± 9.37A125P126G128R130R130C135V453T456T456T456T458 (2)G4304L122A125R130V490 (2)V453V457\*Indicate that two salt bridges are also formed between E124:K460 and E127:K447

The primary residues of the EBOV GP1 that form H-bonds are A124, A125, P126, D/E127, G128, and R130. G128 forms only H-bonds (11 interactions), while A124, A125, D/E127, and R130 form both H-bonding and hydrophobic interactions with ratios 9:3, 5:4, 8:8, and 6:3, respectively. Moreover, the main interactions formed by P126 are hydrophobic (12 out of 13) interactions.

On the other hand, T428, V429, Q449, F451, S452, V453, K460, and V490 are the primary interacting residues from the HSPA5. S452 and K460 only interact through H-bonding (13 and 5 interactions, respectively). F451 and V490 form hydrophobic interactions only (6 interactions for each of them). Meanwhile, the other residues, T428, V429, Q449, and V453, form both H-bonds and hydrophobic contacts with EBOV GP1 (6:3, 4:3, 5:1, and 4:4, respectively). I426 and I459 both form few (3 and 4, respectively) hydrophobic interactions with EBOV GP1, while T458 show three H-bonds, and T434 forms two H-bonds and two hydrophobic contacts with HSPA5. Figure [3a and b](#Fig3){ref-type="fig"} show the docking pose of the EBOV GP1 structure (5JQ3) into HSPA5. In Fig. [3a](#Fig3){ref-type="fig"}, HSPA5 is represented in the green cartoon, while EBOV GP1 is represented in a cyan cartoon with the C121--C135 region in red. The residues involved in the interactions are in line representation and labeled in the enlarged panel. Figure [3b](#Fig3){ref-type="fig"} shows the molecular surface of HSPA5 and EBOV GP1 in cartoon representation. The docking pose shows that EBOV GP1 fits perfectly inside the substrate-binding domain β pocket of HSPA5 with a predicted binding affinity of − 89.4 ± 2.8 Kcal/mol (HADDOCK score).Fig. 3EBOV GP1--HSPA5 docking experiment using HADDOCK. **a** HSPA5 solved structure (5E84) is represented in a green-colored cartoon with the EBOV GP1 solved structure (5JQ3) depicted in the cyan cartoon. The C121--C135 region of EBOV GP1 is represented in a red cartoon for clarification. Amino acids involved in H-bonding or hydrophobic interactions are labeled and expressed in lines. **b** The same docking complex but showing the molecular surface representation of the HSPA5

Pep42 peptide docking versus EBOV GP1 {#Sec7}
-------------------------------------

Table [2](#Tab2){ref-type="table"} shows the docking analysis made by PLIP for the Pep42 peptide after docking into HSPA5 SBDβ. The docking was made by HADDOCK as for the EBOV GP1 docking and by the peptide/protein docking software, HPEPDOCK. Docking scores are listed in the table, along with the interactions that were established after each docking experiment. On average, three H-bonds were formed with S452, T458, and K460 of the HSPA5. Eight hydrophobic interactions were found in the HADDOCK trial with I426, T428, V429, F451, and I459 of the HSPA5, while only five hydrophobic contacts were established in the case of the HPEPDOCK experiment (T428, V429, V432, and I450 of the HSPA5). Compared with EBOV GP1, the peptide Pep42 has the same pattern of interactions with HSPA5 (S452 and K460 for H-bonding while T428, V429, and F451 for hydrophobic contacts). This illustrates the possibility of recognition of the EBOV GP1 for cell-surface HSPA5 overexpressed on cancer cells or cells under other stressors.Table 2The analysis of the docking of the peptide Pe42 (after 200 ns MDS) into GRP78 SBDβ. Data are retrieved by PLIP webserverDocking softwareDocking scoreH-bondingHydrophobic interactionNumberAmino acids involved from EBOV GP1Amino acids involved from GRP78NumberAmino acids involved from EBOV GP1Amino acids involved from GRP78HADDOCK− 74.9 ± 4.53G7Y9Y9T458K460K4608V3Y9 (2)Y9 (2)Y9V10R11V429I426F451I459F451T428HPEPDOCK− 85.53C1C13S452 (2)S4525T2Y9V10V12V429V432T428I450 (2)

The present in silico study predicts the binding mode of EBOV GP1 into the HSPA5 chaperone. Molecular dynamics simulation is suggested as future work to study the dynamics at the binding site and to test some binding inhibitors.

Conclusion {#Sec8}
==========

The Ebola virus, EBOV, is one of the most deadly viral infections in West-African countries. The viral protein GP1 is the crucial host-cell recognizing protein that enables viral entry. HSPA5 overexpression is reported to increase the infectivity of EBOV. Inhibiting HSPA5/EBOV GP1 binding would help in lowering the viral infection. The present work suggests the binding site of the viral/host-cell receptor utilizing in silico methods. This work paves the way for exploring HSPA5/EBOV GP1 binding inhibitors. Further experimental work is required to prove the suggested binding site and to test some inhibitors.
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